James R. Fuchs

7.1k total citations
112 papers, 5.6k citations indexed

About

James R. Fuchs is a scholar working on Molecular Biology, Infectious Diseases and Virology. According to data from OpenAlex, James R. Fuchs has authored 112 papers receiving a total of 5.6k indexed citations (citations by other indexed papers that have themselves been cited), including 62 papers in Molecular Biology, 27 papers in Infectious Diseases and 22 papers in Virology. Recurrent topics in James R. Fuchs's work include HIV/AIDS drug development and treatment (23 papers), HIV Research and Treatment (22 papers) and Biochemical and Molecular Research (13 papers). James R. Fuchs is often cited by papers focused on HIV/AIDS drug development and treatment (23 papers), HIV Research and Treatment (22 papers) and Biochemical and Molecular Research (13 papers). James R. Fuchs collaborates with scholars based in United States, China and Vietnam. James R. Fuchs's co-authors include Raymond L. Funk, Jiayuh Lin, Chenglong Li, Pui‐Kai Li, Mamuka Kvaratskhelia, A. Douglas Kinghorn, Alan Engelman, Masangu Shabangi, Robert A. Flowers and Gregory B. Lesinski and has published in prestigious journals such as Science, Cell and Proceedings of the National Academy of Sciences.

In The Last Decade

James R. Fuchs

111 papers receiving 5.5k citations

Peers

Countries citing papers authored by James R. Fuchs

Since Specialization

Citations

This map shows the geographic impact of James R. Fuchs's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James R. Fuchs with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James R. Fuchs more than expected).

Fields of papers citing papers by James R. Fuchs

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James R. Fuchs. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James R. Fuchs. The network helps show where James R. Fuchs may publish in the future.

Co-authorship network of co-authors of James R. Fuchs

This figure shows the co-authorship network connecting the top 25 collaborators of James R. Fuchs. A scholar is included among the top collaborators of James R. Fuchs based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James R. Fuchs. James R. Fuchs is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Additional Bioactive Silvestrol Analogs from the Roots of Aglaia perviridis Collected in Vietnam 2025 ·Journal of Natural Products ·(unknown), Daniel Adu‐Ampratwum, (unknown), Garima Agarwal, (unknown), Tran Ngoc Ninh, Djaja D. Soejarto, Joanna E. Burdette, James R. Fuchs, A. Douglas Kinghorn, Liva Harinantenaina	1
2	Anti-tumor effects of the eIF4A inhibitor didesmethylrocaglamide and its derivatives in human and canine osteosarcomas 2024 ·Scientific Reports ·Janet L. Oblinger, (unknown), (unknown), Garima Agarwal, (unknown), (unknown), Joelle M. Fenger, James R. Fuchs, A. Douglas Kinghorn, Long‐Sheng Chang	1
3	The structural and mechanistic bases for the viral resistance to allosteric HIV-1 integrase inhibitor pirmitegravir 2024 ·mBio ·(unknown), (unknown), (unknown), (unknown), Arun S. Annamalai, (unknown), (unknown), Franck Amblard, James R. Fuchs, Peter Cherepanov, (unknown), Raymond F. Schinazi, Juan R. Perilla, Baek Kim, Mamuka Kvaratskhelia	2
4	Identification of novel small molecule inhibitors of twin arginine translocation (Tat) pathway and their effect on the control of Campylobacter jejuni in chickens 2024 ·Frontiers in Microbiology ·Löıc Deblais, (unknown), Anand Kumar, (unknown), James R. Fuchs, (unknown), Yosra A. Helmy, Gireesh Rajashekara	1
5	G2Retro as a two-step graph generative models for retrosynthesis prediction 2023 ·Communications Chemistry ·Ziqi Chen, (unknown), James R. Fuchs, Huan Sun, Xia Ning	21
6	Exploration of Verticillins in High-Grade Serous Ovarian Cancer and Evaluation of Multiple Formulations in Preclinical In Vitro and In Vivo Models 2023 ·Molecular Pharmaceutics ·(unknown), Jaqueline Moraes Bazioli, (unknown), Daniel D. Lantvit, Samuel K. Kulp, Kasey Hill, Mitch A. Phelps, Christopher C. Coss, James R. Fuchs, Cedric J. Pearce, Nicholas H. Oberlies, Joanna E. Burdette	3
7	PHY34 inhibits autophagy through V-ATPase V0A2 subunit inhibition and CAS/CSE1L nuclear cargo trafficking in high grade serous ovarian cancer 2022 ·Cell Death and Disease ·(unknown), Alexandria N. Young, (unknown), Melissa R. Pergande, (unknown), (unknown), (unknown), A. Douglas Kinghorn, Xiaoli Zhang, Kiira Ratia, Markus Schirle, Jason R. Thomas, Scott M. Brittain, Claude Shelton, Leslie N. Aldrich, Stephanie M. Cologna, James R. Fuchs, Joanna E. Burdette	25
8	Identification and Optimization of a Novel HIV-1 Integrase Inhibitor 2022 ·ACS Omega ·Daniel Adu‐Ampratwum, (unknown), Pratibha C. Koneru, (unknown), (unknown), Jacques J. Kessl, Patrick R. Griffin, Mamuka Kvaratskhelia, James R. Fuchs, Ross C. Larue	6
9	Discovery of Anticancer Agents of Diverse Natural Origin 2022 ·Journal of Natural Products ·Leslie N. Aldrich, Joanna E. Burdette, Esperanza J. Carcache de Blanco, Christopher C. Coss, Alessandra S. Eustáquio, James R. Fuchs, A. Douglas Kinghorn, (unknown), (unknown), Nicholas H. Oberlies, Jimmy Orjala, Cedric J. Pearce, Mitch A. Phelps, Liva Harinantenaina, Yulin Ren, Djaja D. Soejarto, Brent R. Stockwell, Jack C. Yalowich, Xiaoli Zhang	30
10	Structural and mechanistic bases for a potent HIV-1 capsid inhibitor 2020 ·Science ·S.M. Bester, Guochao Wei, Haiyan Zhao, Daniel Adu‐Ampratwum, (unknown), Valentine V. Courouble, Ashwanth C. Francis, Arun S. Annamalai, Parmit K. Singh, Nikoloz Shkriabai, (unknown), James H. Morrison, Eric M. Poeschla, Alan Engelman, Gregory B. Melikyan, Patrick R. Griffin, James R. Fuchs, Francisco J. Asturias, Mamuka Kvaratskhelia	159
11	Specialized metabolites of the United States lichen Niebla homalea and their antiproliferative activities 2020 ·Phytochemistry ·Yan Zhang, (unknown), Richard W. Spjut, James R. Fuchs, A. Douglas Kinghorn, Liva Harinantenaina	8
12	Phyllanthusmin Derivatives Induce Apoptosis and Reduce Tumor Burden in High-Grade Serous Ovarian Cancer by Late-Stage Autophagy Inhibition 2018 ·Molecular Cancer Therapeutics ·Alexandria N. Young, (unknown), (unknown), (unknown), Daniel D. Lantvit, (unknown), (unknown), Christopher C. Coss, (unknown), Hongyan Wang, Steven M. Swanson, A. Douglas Kinghorn, Xiaoli Zhang, Mitch A. Phelps, Leslie N. Aldrich, James R. Fuchs, Joanna E. Burdette	29
13	Synthesis and antiproliferative activity of derivatives of the phyllanthusmin class of arylnaphthalene lignan lactones 2018 ·Bioorganic & Medicinal Chemistry ·John L. Woodard, (unknown), Pratiq A. Patel, Hee‐Byung Chai, Ragu Kanagasabai, (unknown), Alexandria N. Young, Yulin Ren, (unknown), (unknown), Jack C. Yalowich, A. Douglas Kinghorn, Joanna E. Burdette, James R. Fuchs	24
14	Pentalinonsterol, a Constituent of Pentalinon andrieuxii, Possesses Potent Immunomodulatory Activity and Primes T Cell Immune Responses. 2017 ·Europe PMC (PubMed Central) ·Steve Oghumu, Sanjay Varikuti, Noushin Saljoughian, César Terrazas, (unknown), Narasimham L. Parinandi, James R. Fuchs, A. Douglas Kinghorn, Abhay R. Satoskar	14
15	Trichormamides C and D, antiproliferative cyclic lipopeptides from the cultured freshwater cyanobacterium cf. Oscillatoria sp. UIC 10045 2015 ·Bioorganic & Medicinal Chemistry ·Shangwen Luo, Hahk‐Soo Kang, Aleksej Krunić, Wei-Lun Chen, (unknown), John L. Woodard, James R. Fuchs, Sang‐Hyun Cho, Scott G. Franzblau, Steven M. Swanson, Jimmy Orjala	25
16	A Critical Role of the C-terminal Segment for Allosteric Inhibitor-induced Aberrant Multimerization of HIV-1 Integrase 2014 ·Journal of Biological Chemistry ·Nikoloz Shkriabai, Venkatasubramanian Dharmarajan, Alison Slaughter, Jacques J. Kessl, Ross C. Larue, Lei Feng, James R. Fuchs, Patrick R. Griffin, Mamuka Kvaratskhelia	24
17	Pancreatic Cancer-Associated Stellate Cells Promote Differentiation of Myeloid-Derived Suppressor Cells in a STAT3-Dependent Manner 2013 ·Cancer Research ·Thomas A. Mace, Zeenath Ameen, Amy Collins, Sylwia E. Wojcik, Markus Mair, Gregory Young, James R. Fuchs, Timothy D. Eubank, Wendy L. Frankel, Tanios Bekaii‐Saab, Mark Bloomston, Gregory B. Lesinski	344
18	HAb18G/CD147 Promotes pSTAT3-Mediated Pancreatic Cancer Development via CD44s 2013 ·Clinical Cancer Research ·Ling Li, Wenhua Tang, Xiaoqing Wu, David Karnak, Xiaojie Meng, R. Thompson, Xinbao Hao, Yongmin Li, Xiaotan T. Qiao, Jiayuh Lin, James R. Fuchs, Diane M. Simeone, Zhi‐Nan Chen, Theodore S. Lawrence, Liang Xu	57
19	Novel STAT3 Phosphorylation Inhibitors Exhibit Potent Growth-Suppressive Activity in Pancreatic and Breast Cancer Cells 2010 ·Cancer Research ·Li Lin, Brian Hutzen, Mingxin Zuo, Sarah Ball, Stephanie Deangelis, Elizabeth Foust, Bulbul Pandit, Michael A. Ihnat, Satyendra S. Shenoy, Samuel K. Kulp, Pui‐Kai Li, Chenglong Li, James R. Fuchs, Jiayuh Lin	197
20	IL-6, a risk factor for hepatocellular carcinoma: FLLL32 inhibits IL-6-Induced STAT3 phosphorylation in human hepatocellular cancer cells 2010 ·Cell Cycle ·Yan Liu, James R. Fuchs, Chenglong Li, Jiayuh Lin	62

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact